The Birth Control Shot
Was Linked to
Brain Tumors.
Studies published in peer-reviewed journals documented a significantly elevated meningioma risk in patients who used Depo-Provera long-term. The FDA required Pfizer to add a black box warning in 2024. Pfizer had access to this research and failed to update its labeling for years. Attorneys handling Depo-Provera meningioma lawsuits and settlements are reviewing claims in MDL 3140 nationwide.
Litigation Status
Peer-Reviewed Research.
Years of Silence.
A landmark 2024 study in the British Medical Journal found that long-term Depo-Provera users faced a markedly elevated risk of intracranial meningioma. The FDA acted. Pfizer updated its label. What took years is now the foundation of a growing federal MDL against the company.
Depo-Provera meningioma lawsuits are consolidated in MDL 3140 — In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation — in the Northern District of Illinois before Judge Matthew Kennelly. The docket is expanding rapidly and new claims are actively being filed.
The FDA required Pfizer and other depot medroxyprogesterone acetate manufacturers to add a black box warning — the most serious warning available — about the elevated risk of intracranial meningioma associated with long-term use. The gap between available evidence and this mandatory disclosure is central to all Depo-Provera failure-to-warn claims.
Attorneys in this network handle Depo-Provera lawsuit and meningioma settlement claims on pure contingency. No retainer. No hourly billing. No upfront fees. If no compensation is recovered on your behalf, you owe nothing — period.
"The research existed. The warning didn't. Pfizer made that choice."
Injuries & Legal Theories
What Depo-Provera Lawsuits
Are Built On
Depo-Provera meningioma lawsuits rest on Pfizer's failure to warn — the company had access to epidemiological data linking DMPA to meningioma risk, collected adverse event reports from patients and prescribers, and failed to update product labeling with an adequate warning before the FDA's 2024 mandate. A connected attorney will assess which claims apply to your situation at no cost.
Depo-Provera Meningioma Lawsuit — Failure to Warn Against Pfizer
The central claim in Depo-Provera litigation is that Pfizer knew or should have known — from peer-reviewed studies, international pharmacovigilance data, and adverse event reporting — that long-term use of depot medroxyprogesterone acetate was associated with a significantly elevated risk of intracranial meningioma, and failed to disclose this risk to patients or prescribing physicians before the FDA required it in 2024.
Intracranial Meningioma Requiring Surgery — Craniotomy & Resection Claims
Meningiomas arising in proximity to critical structures — the brain, spinal cord, optic nerves, or major blood vessels — frequently require open surgical removal. Patients who underwent craniotomy or stereotactic procedures to remove a meningioma diagnosed during or after long-term Depo-Provera use may have claims for the surgical costs, recovery, neurological complications, and documented link between DMPA exposure and tumor development.
Radiation Treatment for Meningioma After Depo-Provera Use
Meningiomas that are inoperable, recurrent, or located in surgically inaccessible regions are frequently treated with stereotactic radiosurgery or conventional radiation. Patients who received radiation treatment for a meningioma diagnosed following long-term Depo-Provera use — and who were not warned of this risk at the time of prescription — may have viable claims for radiation-related harm in addition to the underlying tumor diagnosis.
Neurological Harm — Vision Loss, Seizures & Cognitive Impairment From Meningioma
Depending on location, meningiomas can cause severe and sometimes permanent neurological harm — including vision loss or blindness, seizures, hearing loss, limb weakness, memory impairment, and personality or cognitive changes. Where these neurological deficits are linked to a meningioma diagnosed in the context of long-term DMPA use, claims for permanent disability and diminished quality of life carry significant weight in Depo-Provera lawsuit valuations.
Watch-and-Wait Meningioma — Ongoing Monitoring & Medical Surveillance Claims
Not all meningiomas are immediately treated surgically. Many patients are placed on active surveillance programs — periodic MRI imaging, neurological examinations, and oncology consultations that impose ongoing medical costs, anxiety, and life disruption. Patients who are being monitored for a DMPA-linked meningioma but have not yet required surgery may still have viable claims for the harm caused by the diagnosis itself and the burden of ongoing medical surveillance.
Recurrent Meningioma & Long-Term Medical Consequences of DMPA Exposure
Meningiomas have a documented recurrence rate following surgical or radiological treatment. Patients who have experienced meningioma recurrence — requiring additional surgery, additional radiation, or escalating medical management — may have enhanced claims reflecting the cumulative harm of an ongoing condition that originated in a Pfizer product distributed without adequate risk disclosure.
Eligibility
Signs Your Situation
May Support a Claim
The core question is whether you used Depo-Provera for an extended period and were subsequently diagnosed with an intracranial meningioma — without being warned that the birth control shot carried this risk. A connected attorney makes the final determination at no cost.
You received Depo-Provera injections for one year or more as prescribed contraception
The meningioma risk documented in research studies and cited by the FDA is associated with longer-term use of depot medroxyprogesterone acetate — generally one year or more of injections administered every three months. Duration of use is a key qualifying factor that a connected attorney will assess as part of a free case evaluation.
You were diagnosed with an intracranial meningioma during or after your Depo-Provera use
A meningioma diagnosis — confirmed by MRI, CT, or surgical pathology — is the qualifying injury in Depo-Provera litigation. The timing of your diagnosis relative to your DMPA use history is evaluated by a connected attorney to assess the strength of the causal link supporting your claim.
Your meningioma required surgery, radiation, or is being monitored with ongoing imaging
The nature and severity of your medical treatment — whether surgical resection, stereotactic radiosurgery, or active surveillance — directly affects the valuation of your Depo-Provera meningioma claim. All three treatment pathways may support a viable lawsuit. A connected attorney can assess your specific situation at no cost.
You experienced neurological symptoms — headaches, vision changes, seizures, or cognitive issues — associated with your meningioma
Neurological symptoms caused or worsened by a meningioma — persistent headaches, vision disturbances, seizure activity, hearing loss, cognitive changes, or motor deficits — significantly affect the damages available in a Depo-Provera lawsuit. These consequences of Pfizer's failure to warn are central to claims for pain and suffering and diminished quality of life.
You were not warned about the meningioma risk when Depo-Provera was prescribed to you
Every patient prescribed Depo-Provera before Pfizer's 2024 label update was denied the informed consent the law required. If your prescriber had no warning to pass along — because Pfizer withheld it from the labeling — the failure-to-warn chain runs directly from Pfizer to you. A connected attorney can assess this element of your claim at no cost.
Your meningioma diagnosis falls within the statute of limitations window
Statutes of limitation for Depo-Provera lawsuits vary by state — typically two to three years from diagnosis or from when you connected your meningioma to your DMPA use. With MDL 3140 actively developing, filing promptly is strongly advisable. A connected attorney can confirm the exact deadline that applies in your state at no cost.
How It Works
No Upfront Costs.
MDL Filed for You.
Attorneys in this network manage the complete Depo-Provera lawsuit process — from free evaluation through MDL 3140 filing and beyond. Your role is sharing your medical history. They handle everything else.
Free Confidential Evaluation
A connected attorney reviews your Depo-Provera injection history and your meningioma diagnosis. You'll quickly learn whether your situation qualifies for MDL 3140 — no cost, no obligation to proceed.
Medical & Prescription Records
Injection records, pharmacy documentation, imaging studies, neurosurgical records, radiation treatment history, and neurological evaluations are gathered to establish both your DMPA exposure and the full extent of meningioma-related harm — the evidentiary foundation of your claim against Pfizer.
Filing Into MDL 3140
Your Depo-Provera lawsuit is filed against Pfizer and coordinated through MDL 3140 in the Northern District of Illinois. Science panel rulings, expert discovery, and bellwether trial outcomes will inform your case as the MDL advances toward global resolution.
Settlement or Resolution
Attorneys in this network collect a contingency fee only from your recovery. There is nothing to pay at any point — no retainer, no hourly billing, no upfront fees of any kind.
From Those Who Filed
Their Words
"I was on Depo for nine years. At 38 I was told I had a meningioma pressing on my optic nerve. I'd never heard of this connection. When a connected attorney explained the MDL, I felt like I finally had somewhere to go with this."
"The surgery to remove my meningioma took eight hours. My recovery took two years. My OB-GYN had been prescribing Depo for over a decade and had no idea this was a known risk. The FDA warning came out two months after my craniotomy."
"My neurologist told me my meningioma was 'likely hormone-driven.' I'd been on Depo since my early twenties. Nobody ever mentioned brain tumors — not once in fifteen years of injections. The free case review was thirty minutes and worth every second."
Common Questions
What You Need to Know
Yes. Depo-Provera meningioma lawsuits are active and consolidated in MDL 3140 in the Northern District of Illinois. Claims allege Pfizer failed to warn patients and prescribers that long-term depot medroxyprogesterone acetate use was associated with a significantly elevated risk of intracranial meningioma — before the FDA required a black box warning in 2024. Submit your information for a free evaluation to find out if your situation qualifies.
Studies — including a prominent 2024 study published in the British Medical Journal — found that long-term use of depot medroxyprogesterone acetate (Depo-Provera) was associated with a statistically significant elevated risk of intracranial meningioma. Meningiomas can cause vision loss, seizures, cognitive impairment, and require surgery or radiation depending on location and growth. The FDA required Pfizer to disclose this risk in 2024. A connected attorney can assess whether your diagnosis qualifies.
MDL 3140 consolidates Depo-Provera meningioma lawsuits in the Northern District of Illinois, enabling coordinated expert discovery, science panel proceedings, and bellwether trials that benefit all plaintiffs. Your individual case retains its identity within the MDL. Attorneys in this network are filing Depo-Provera claims directly into MDL 3140. A connected attorney can walk you through the process at no cost.
Depo-Provera meningioma settlement values depend on the size and location of the tumor, whether surgery or radiation was required, neurological deficits experienced, duration of DMPA use, and documented impact on employment and quality of life. Because MDL 3140 is still in active development, global settlement benchmarks have not yet been established. A connected attorney can assess your individual claim's value during a free, confidential review.
Yes. In 2024 the FDA required Pfizer and other depot medroxyprogesterone acetate manufacturers to add a black box warning about the increased risk of intracranial meningioma associated with long-term use. The FDA's action followed peer-reviewed research including a 2024 BMJ study documenting elevated meningioma risk. The gap between available evidence and this required warning is central to all Depo-Provera failure-to-warn claims. See if the labeling gap applies to your claim.
The studies linking Depo-Provera to meningioma risk identified elevated risk associated with longer-term use — generally one year or more of DMPA injections. Depo-Provera is administered every three months, meaning four or more injections per year. Each case is evaluated individually. A connected attorney can assess your specific use history and meningioma diagnosis at no cost.
Yes. Statutes of limitation for Depo-Provera lawsuits vary by state — typically two to three years from meningioma diagnosis or from when you connected the diagnosis to your DMPA use. With MDL 3140 building momentum, filing sooner is strongly advisable. Contact a connected attorney today to confirm the exact deadline in your state.
Pfizer Had the Research.
Patients Weren't Told.
The evaluation is free. The consultation is confidential. There is no obligation until you choose to move forward.